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Tamoxifen has been shown over the past 30 years to be 
extremely eﬀ  ective in the treatment of estrogen receptor 
(ER)-positive breast cancer. Th  e drug is widely used in 
the adjuvant setting where it reduces the risk of breast 
cancer recurrence by almost 40% and the risk of death 
from breast cancer by one-third [1]. It is now known that 
tamoxifen acts as a pro-drug. Its major active metabolites 
are N-desmethyl tamoxifen, which has a low aﬃ   nity for 
ER, 4-hydroxy tamoxifen (4HT) and 4-hydroxy-N-
desmethyl-tamoxifen (endoxifen). Endoxifen and 4HT 
have by far the highest aﬃ   nity for ER and since endoxifen 
is produced in six to ten times the concentration of 4HT 
it is felt to be the most important metabolite.
CYP2D6 is an enzyme of the cytochrome P450 family, 
subfamily D, found on chromosome 22. It catalyzes 
tamoxifen’s metabolism and is encoded by a large poly-
morphic gene with more than 80 allelic mutations 
identiﬁ   ed. Inherited variations alter the function of 
CYP2D6 and the geographic and ethnic distributions of 
these polymorphisms are varied. Drugs given concur-
rently can also alter the function of CYP2D6 by 
competing for its activity.
Th  e metabolic pathway of tamoxifen is shown in 
Figure  1. As can be seen, CYP2D6 catalyzes both 
tamoxifen’s primary and secondary metabolism.
CYP2D6 phenotypic expression can be divided into 
three groups: those with little or no enzyme activity 
(poor or intermediate metabolizers); those with normal 
enzyme activity (extensive metabolizers); and those with 
greatly increased enzyme activity (ultrarapid metabo-
lizers). Several studies have shown that relapse free time 
and disease free survival as well as overall survival in 
women treated in the adjuvant setting with tamoxifen 
vary according to the presence of variants that produce 
ultrarapid, intermediate or low metabolism [2]. Results 
are, however, contradictory, with at least ten studies 
showing positive association between these genotypes 
and outcome and another eight showing no association 
[3]. Th   us, evidence is contradictory as to how important 
CYP2D6 levels are to outcome with adjuvant tamoxifen 
therapy. Th   e ideal study to conﬁ  rm or refute the value of 
this association would be a randomized trial of tamoxifen 
versus no treatment as adjuvant therapy with these 
enzymes and endoxifen levels measured and correlated 
with the outcomes of recurrence and survival.
In addition, a number of common drugs are known to 
be inhibitors of CYP2D6. Strong inhibitors include drugs 
such as chlorpromazine, ﬂ  uoxetine, miconazole, paroxe-
tine, quinidine and quinine whereas moderate inhibitors 
include cimetidine, diphenhydramine, haloperidol, keto-
conazole, methadone, nicardipine and sertraline. Some 
selective serotonin receptor inhibitor (SSRI) anti  depres-
sants, such as venlafaxine (Eﬀ   exor), are quite weak 
inhibitors of CYP2D6 activity.
Kelly and colleagues [4] have recently shown in an 
observational population-based study from Ontario, 
Canada that women prescribed antidepressants, in 
particular paroxitene, concomitantly with tamoxifen 
adjuvant treatment had increasing breast cancer-related 
and/or all cause mortality whereas patients treated with 
the concomitant use of other antidepressants that are not 
such strong inhibitors, such as sertraline, ﬂ  uvoxamine, 
ﬂ  uoxetine and particularly venlafaxine, did not have this 
eﬀ  ect. Again, the interpretation of this study is limited by 
its observational design and the lack of measurement of 
endoxifen levels, which could help to draw the sort of 
direct conclusion one might like.
In summary, tamoxifen pharmacogenetic studies in the 
past 20 years have detected a new active metabolite, 
endoxifen, which is likely most important in predicting 
outcome in relation to adjuvant therapy with tamoxifen. 
Several recent studies show a clear negative interaction 
between paroxitene and tamoxifen metabolism to 
endoxifen while other SSRIs such as venlafaxine do not 
appear to produce this eﬀ   ect. While it is clear that 
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phenotype, no consensus has been reached regarding the 
incorporation of CYP2D6 genotype testing in routine 
clinical practice, although an excellent recent review of 
this subject suggests that such testing may be useful [5]. 
Decisions to conduct genotype testing should still be 
individualized based on clinical indication and patient 
preference. Clinical trials to clarify this situation should 
be well designed, adequately powered prospective studies 
with strict inclusion criteria, genotype testing and 
endoxifen levels.
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Figure 1. Metabolic pathway of tamoxifen.
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